Knockdown of LncRNA H19 Alleviates Ox-LDL-induced HCAECs Inflammation and Injury by Mediating MiR-20a-5p/HDAC4 Axis

Overview

Journal Inflamm Res

Specialties Allergy & Immunology
Pathology

Date 2022 Jul 19

PMID 35854140

Authors

Yilin Yang

Zhaofei Wang

Ying Xu

Xiaofang Liu

Yehai Sun

Wei Li

Affiliations

Soon will be listed here.

Abstract

Background: Coronary artery disease (CAD) seriously disturbs the life of people. LncRNA H19 is reported to promote the progression of CAD; Nevertheless, the detailed mechanism by which H19 modulates CAD development is unclear.

Methods: Clinical samples of CAD patients were collected, meanwhile we established in vitro and in vivo models of CAD by treating HCAECs with ox-LDL and feeding ApoE mice with high fat diets (HFD). MTT assay was adopted to assess the cell viability. Transwell detection was applied to test the migration, and apoptosis was tested by flow cytometry. The levels of inflammatory cytokines were examined by ELISA. The relation among H19, miR-20a-5p and HDAC4 was explored by dual luciferase reporter and RIP assay.

Results: H19 and HDAC4 levels were elevated, while miR-20a-5p was reduced in plasma of CAD patients and ox-LDL-treated HCAECs. ox-LDL increased H19 level and induced apoptosis and inflammation in HCAECs, while silencing of H19 rescued this phenomenon. In addition, the level of H19 was negatively correlated with miR-20a-5p, and miR-20a-5p inhibitor restored the effect of H19 silencing on HCAECs function. HDAC4 was the downstream mRNA of miR-20a-5p, and miR-20a-5p upregulation reversed ox-LDL-induced HCAECs injury through targeting HDAC4. Furthermore, H19 silencing significantly alleviated the coronary atherosclerotic plaques and inhibited the inflammatory responses in vivo.

Conclusions: We proved that knockdown of H19 alleviated ox-LDL-induced HCAECs injury via miR-20a-5p/HDAC4 axis, which might provide a new tactics against CAD.

Citing Articles

Echinacoside activates Nrf2/PPARγ signaling pathway to modulate mitochondrial fusion-fission balance to ameliorate ox-LDL-induced dysfunction of coronary artery endothelial cells.

Qiu X, Feng Y Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9767-9776.

PMID: 38916831 DOI: 10.1007/s00210-024-03233-1.

Roles of long noncoding RNAs in human inflammatory diseases.

Zhang Y, Liu H, Niu M, Wang Y, Xu R, Guo Y Cell Death Discov. 2024; 10(1):235.

PMID: 38750059 PMC: 11096177. DOI: 10.1038/s41420-024-02002-6.

LncRNAs in Kawasaki disease and Henoch-Schönlein purpura: mechanisms and clinical applications.

Yang K, Tang J, Li H, Zhang H, Ding J, Li Z Mol Cell Biochem. 2023; 479(8):1969-1984.

PMID: 37639198 DOI: 10.1007/s11010-023-04832-x.

Immune Cell Infiltration Analysis Based on Bioinformatics Reveals Novel Biomarkers of Coronary Artery Disease.

He T, Muhetaer M, Wu J, Wan J, Hu Y, Zhang T J Inflamm Res. 2023; 16:3169-3184.

PMID: 37525634 PMC: 10387251. DOI: 10.2147/JIR.S416329.

Serum histone deacetylase 4 longitudinal change for estimating major adverse cardiovascular events in acute coronary syndrome patients receiving percutaneous coronary intervention.

Xu H, Zhang J, Jia H, Xing F, Cong H Ir J Med Sci. 2023; 192(6):2689-2696.

PMID: 36849652 DOI: 10.1007/s11845-023-03326-5.

References

Kai H, Wu Q, Yin R, Tang X, Shi H, Wang T . LncRNA NORAD Promotes Vascular Endothelial Cell Injury and Atherosclerosis Through Suppressing Gene Transcription Enhancing H3K9 Deacetylation by Recruiting HDAC6. Front Cell Dev Biol. 2021; 9:701628. PMC: 8301222. DOI: 10.3389/fcell.2021.701628. View

Radecke C, Warrick A, Singh G, Rogers J, Simon S, Armstrong E . Coronary artery endothelial cells and microparticles increase expression of VCAM-1 in myocardial infarction. Thromb Haemost. 2014; 113(3):605-16. PMC: 4479188. DOI: 10.1160/TH14-02-0151. View

Guo F, Tang C, Li Y, Liu Y, Lv P, Wang W . The interplay of LncRNA ANRIL and miR-181b on the inflammation-relevant coronary artery disease through mediating NF-κB signalling pathway. J Cell Mol Med. 2018; 22(10):5062-5075. PMC: 6156284. DOI: 10.1111/jcmm.13790. View

Jin H, Zhu Y, Wang X, Luo E, Li Y, Wang B . BDNF corrects NLRP3 inflammasome-induced pyroptosis and glucose metabolism reprogramming through KLF2/HK1 pathway in vascular endothelial cells. Cell Signal. 2020; 78:109843. DOI: 10.1016/j.cellsig.2020.109843. View

Chen S, Sun Y, Neoh K, Chen A, Li W, Yang X . Microfluidic assay of circulating endothelial cells in coronary artery disease patients with angina pectoris. PLoS One. 2017; 12(7):e0181249. PMC: 5509377. DOI: 10.1371/journal.pone.0181249. View

Zeng M, Yan X, Wu W . Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis. BMC Cardiovasc Disord. 2021; 21(1):446. PMC: 8447745. DOI: 10.1186/s12872-021-02259-0. View

Wang J, Su Z, Lu S, Fu W, Liu Z, Jiang X . LncRNA HOXA-AS2 and its molecular mechanisms in human cancer. Clin Chim Acta. 2018; 485:229-233. DOI: 10.1016/j.cca.2018.07.004. View

Li L, Wang L, Li H, Han X, Chen S, Yang B . Characterization of LncRNA expression profile and identification of novel LncRNA biomarkers to diagnose coronary artery disease. Atherosclerosis. 2018; 275:359-367. DOI: 10.1016/j.atherosclerosis.2018.06.866. View

Chen J, Dang J . LncRNA CASC11 was downregulated in coronary artery disease and inhibits transforming growth factor-1. J Int Med Res. 2020; 48(3):300060519889187. PMC: 7133399. DOI: 10.1177/0300060519889187. View

10.

Tan J, Liu S, Jiang Q, Yu T, Huang K . LncRNA-MIAT Increased in Patients with Coronary Atherosclerotic Heart Disease. Cardiol Res Pract. 2019; 2019:6280194. PMC: 6501139. DOI: 10.1155/2019/6280194. View

11.

Wang H, Zhang N, Li G, Xu B . Proinflammatory cytokine IFN-γ, lncRNA BANCR and the occurrence of coronary artery disease. Life Sci. 2019; 231:116510. DOI: 10.1016/j.lfs.2019.05.066. View

12.

Zhang Z, Gao W, Long Q, Zhang J, Li Y, Liu D . Increased plasma levels of lncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population. Sci Rep. 2017; 7(1):7491. PMC: 5548926. DOI: 10.1038/s41598-017-07611-z. View

13.

Bernardo B, Ooi J, Lin R, McMullen J . miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart. Future Med Chem. 2015; 7(13):1771-92. DOI: 10.4155/fmc.15.107. View

14.

Agiannitopoulos K, Samara P, Papadopoulou M, Efthymiadou A, Papadopoulou E, Tsaousis G . miRNA polymorphisms and risk of premature coronary artery disease. Hellenic J Cardiol. 2020; 62(4):278-284. DOI: 10.1016/j.hjc.2020.01.005. View

15.

Schulte C, Karakas M, Zeller T . microRNAs in cardiovascular disease - clinical application. Clin Chem Lab Med. 2016; 55(5):687-704. DOI: 10.1515/cclm-2016-0576. View

16.

Yin Z, Zhou Y, Ma T, Chen S, Shi N, Zou Y . Down-regulated lncRNA SBF2-AS1 in M2 macrophage-derived exosomes elevates miR-122-5p to restrict XIAP, thereby limiting pancreatic cancer development. J Cell Mol Med. 2020; 24(9):5028-5038. PMC: 7205800. DOI: 10.1111/jcmm.15125. View

17.

Wang D, Wang Y, Ma J, Wang W, Sun B, Zheng T . MicroRNA-20a participates in the aerobic exercise-based prevention of coronary artery disease by targeting PTEN. Biomed Pharmacother. 2017; 95:756-763. DOI: 10.1016/j.biopha.2017.08.086. View

18.

Luo L, Martin S, Parkington J, Cadena S, Zhu J, Ibebunjo C . HDAC4 Controls Muscle Homeostasis through Deacetylation of Myosin Heavy Chain, PGC-1α, and Hsc70. Cell Rep. 2019; 29(3):749-763.e12. DOI: 10.1016/j.celrep.2019.09.023. View

19.

Zhang B, Dong Y, Liu M, Yang L, Zhao Z . miR-149-5p Inhibits Vascular Smooth Muscle Cells Proliferation, Invasion, and Migration by Targeting Histone Deacetylase 4 (HDAC4). Med Sci Monit. 2019; 25:7581-7590. PMC: 6796703. DOI: 10.12659/MSM.916522. View

20.

Gordon J, Pagiatakis C, Salma J, Du M, Andreucci J, Zhao J . Protein kinase A-regulated assembly of a MEF2{middle dot}HDAC4 repressor complex controls c-Jun expression in vascular smooth muscle cells. J Biol Chem. 2009; 284(28):19027-42. PMC: 2707197. DOI: 10.1074/jbc.M109.000539. View